Immuron Limited – American Depositary Shares (NASDAQ:IMRN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Friday, March 9th. They currently have a $20.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 73.76% from the company’s current price.
IMRN stock remained flat at $$11.51 on Friday. 1,431 shares of the company traded hands, compared to its average volume of 16,864. Immuron Limited – American Depositary Shares has a 1 year low of $4.47 and a 1 year high of $16.70.
About Immuron Limited – American Depositary Shares
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.
Receive News & Ratings for Immuron Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.